Accessibility Menu
Avanos Medical logo

Avanos Medical(NYSE) AVNS

This security has been delisted. This page is retained for historical reference.

Avanos Medical last closing stock price
MetricPriceDate
Last closeUSD 24.992026-07-24
Avanos Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.08%USD 24.972026-07-17
1 month+0.16%USD 24.952026-06-24
3 month+1.34%USD 24.662026-04-24
Year to date+122.53%USD 11.232025-12-31
1 year+110.35%USD 11.882025-07-24
3 year+2.21%USD 24.452023-07-25
5 year-28.09%USD 34.752021-07-23
Since inception-37.13%USD 39.752014-10-22

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

AVNS Financials

Key Financial Metrics (TTM)

Gross Margin

48.55%

Operating Margin

-7.92%

Net Income Margin

-9.69%

Return on Equity

-8.91%

Return on Capital

-6.79%

Return on Assets

-6.61%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$347.60M

Operating Income

-$56.70M

EBITDA

-$21.60M

Operating Cash Flow

$36.70M

Capital Expenditure

-$29.20M

Free Cash Flow

$7.50M

Cash & ST Invst.

$65.60M

Total Debt

$138.40M

Avanos Medical Performance Analysis

Avanos Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 684,100,000-8.1%
20232023-12-31USD 673,300,000-1.6%
20242024-12-31USD 687,800,0002.2%
20252025-12-31USD 701,200,0001.9%
Avanos Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.5%
Q32025-09-301.6%
Q42025-12-311.7%
Q12026-03-310.7%
Avanos Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.07723.8%
20232023-12-31USD -1.33N/A
20242024-12-31USD -8.52542.7%
20252025-12-31USD -1.57-81.5%
Avanos Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1285.7%
Q32025-09-3098.2%
Q42025-12-31363.9%
Q12026-03-3138.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$182.20M

+8.8%

Gross Profit

$88.40M

-1.6%

Gross Margin

48.52%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2,287

N/A

Net Income

$5.10M

-22.7%

EBITDA

$19.30M

-9.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$65.60M

-32.4%

Total Debt

$138.40M

-1.8%

Accounts Receivable

$103.00M

-1.7%

Inventory

$141.30M

+2.3%

Long Term Debt

$117.10M

-3.3%

Short Term Debt

$21.30M

+7.6%

Return on Assets

-6.61%

N/A

Return on Invested Capital

-6.17%

N/A

Free Cash Flow

-$16.60M

-187.4%

Operating Cash Flow

-$12.30M

-147.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AORTArtivion, Inc.
$28.90+2.05%
AXGNAxoGen, Inc.
$50.19+2.12%
CVSACovista Inc.
$131.46-0.65%
ITGRInteger Holdings Corporation
$125.09+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.